The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 28, 2021

Filed:

Mar. 25, 2019
Applicants:

Vegenics Pty Limited, South Yarra, AU;

The Schepens Eye Research Institute, Inc., Boston, MA (US);

Inventors:

Megan E. Baldwin, Brighton East, AU;

Kameran Lashkari, Boston, MA (US);

Jie Ma, Boston, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/16 (2006.01); G01N 33/74 (2006.01); A61K 38/17 (2006.01); G01N 33/68 (2006.01); A61K 9/00 (2006.01); A61K 38/45 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
G01N 33/74 (2013.01); A61K 38/179 (2013.01); A61K 9/0048 (2013.01); A61K 38/45 (2013.01); A61K 39/395 (2013.01); C12Y 207/10001 (2013.01); G01N 33/68 (2013.01); G01N 2333/475 (2013.01); G01N 2800/16 (2013.01); G01N 2800/164 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7014 (2013.01);
Abstract

The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.


Find Patent Forward Citations

Loading…